- Home
- TNGX vs GCMG Comparison
TNGX vs GCMG Comparison
Compare TNGX & GCMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- GCMG
- Stock Information
- Founded
- TNGX 2014
- GCMG 1971
- Country
- TNGX United States
- GCMG United States
- Employees
- TNGX N/A
- GCMG N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- GCMG Finance/Investors Services
- Sector
- TNGX Health Care
- GCMG Finance
- Exchange
- TNGX Nasdaq
- GCMG Nasdaq
- Market Cap
- TNGX 723.2M
- GCMG 631.4M
- IPO Year
- TNGX N/A
- GCMG N/A
- Fundamental
- Price
- TNGX $7.58
- GCMG $11.92
- Analyst Decision
- TNGX Strong Buy
- GCMG Buy
- Analyst Count
- TNGX 6
- GCMG 4
- Target Price
- TNGX $10.00
- GCMG $15.13
- AVG Volume (30 Days)
- TNGX 2.6M
- GCMG 715.8K
- Earning Date
- TNGX 11-05-2025
- GCMG 11-07-2025
- Dividend Yield
- TNGX N/A
- GCMG 3.70%
- EPS Growth
- TNGX N/A
- GCMG N/A
- EPS
- TNGX N/A
- GCMG 0.19
- Revenue
- TNGX $24,296,000.00
- GCMG $533,097,999.00
- Revenue This Year
- TNGX $20.42
- GCMG $4.88
- Revenue Next Year
- TNGX N/A
- GCMG $11.78
- P/E Ratio
- TNGX N/A
- GCMG $64.02
- Revenue Growth
- TNGX N/A
- GCMG 15.56
- 52 Week Low
- TNGX $1.03
- GCMG $10.91
- 52 Week High
- TNGX $8.80
- GCMG $14.48
- Technical
- Relative Strength Index (RSI)
- TNGX 51.87
- GCMG 32.38
- Support Level
- TNGX $7.66
- GCMG $11.66
- Resistance Level
- TNGX $8.80
- GCMG $13.03
- Average True Range (ATR)
- TNGX 0.51
- GCMG 0.27
- MACD
- TNGX -0.04
- GCMG -0.10
- Stochastic Oscillator
- TNGX 33.70
- GCMG 16.67
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.